Vasoactive intestinal peptide (VIP) is an important modulator of hippocampal synaptic transmission that influences both GABAergic synaptic transmission and glutamatergic cell excitability through activation of VPAC 1 and VPAC 2 receptors. Presynaptic enhancement of GABA release contributes to VIP modulation of hippocampal synaptic transmission.
Introduction
Vasoactive intestinal peptide (VIP) modulates hippocampal synaptic transmission and excitability (Yang et al., 2010) and is present in the hippocampus exclusively in interneurones (Acsády et al., 1996a) . As such, most of its actions are dependent on GABAergic transmission (Wang et al., 1997; Cunha-Reis et al., 2004) . VIP modulation of GABAergic transmission occurs both at the presynaptic component, by modulating GABA release, and at the postsynaptic component, by modulating GABAergic currents (Wang et al., 1997; Cunha-Reis et al., 2004 , 2008 . These GABAergic-dependent effects of VIP are also important in the regulation of hippocampal synaptic plasticity (CunhaReis et al., 2010 (CunhaReis et al., , 2014 . VIP has also postsynaptic actions on pyramidal cells that are independent of GABAergic transmission (Cunha-Reis et al., 2006) .
In the hippocampus, two selective high-affinity VIP receptors: VPAC 1 and VPAC 2 receptors that belong to the class II family of GPCRs (White et al., 2010; Yang et al., 2010) have been identified by in situ hybridization, autoradiography and immunohistochemistry (Joo et al., 2004; White et al., 2010) . These receptors are encoded by two different genes, share only 55% similarity and have similar affinities for VIP. A third receptor (PAC 1 ) binds VIP with much lower affinity (White et al., 2010; Harmar et al., 2012) . All three receptors also recognize, with high affinity, the pituitary adenylate cyclase-activating peptide (PACAP). Both VPAC 1 and VPAC 2 receptors are involved in the modulation of hippocampal synaptic transmission and synaptic plasticity by VIP (Cunha-Reis et al., 2005 . This suggests that both receptors may be involved in the regulation of GABA release. As neuropeptide receptors have been proposed as important targets for the development of anticonvulsive drugs (Clynen et al., 2014) , studying their role in the modulation of GABA release is of particular clinical relevance. VPAC 1 and VPAC 2 receptors are positively coupled to adenylate cyclase by G s activation in most tissues (White et al., 2010; Harmar et al., 2012) . Postsynaptic excitatory actions of VIP in hippocampal pyramidal cells involve either cAMP or cAMP-dependent mechanisms (Haas and Gähwiler, 1992; Haug and Storm, 2000; Ciranna and Cavallaro, 2003) , and VIP-mediated enhancement of mIPSCs in hippocampal cell cultures occurs through a PKA-dependent mechanism (Wang et al., 1997) . However, VPAC 1 and VPAC 2 receptors can also couple to other signalling/G protein-dependent mechanisms in different brain preparations (Fatatis et al., 1994; Gressens et al., 1998; Nielsen et al., 2002) . Furthermore, VPAC 1 receptor couples to G i/o proteins in the hippocampus (Shreeve, 2002) , and VPAC 1 -mediated enhancement of synaptic transmission in the CA1 area of the hippocampus is dependent on both PKA and PKC activity (Cunha-Reis et al., 2005) . This suggests that VIP receptors can couple to different signalling pathways in the hippocampus.
Hippocampal inhibitory and excitatory circuits are tightly interconnected, making it difficult to discriminate between the actions of VIP on release of inhibitory and excitatory transmitters in vivo or in a slice preparation. Isolated nerve terminal preparations are virtually free of connections with other neuronal components and have been successfully used to evaluate presynaptic modulation of neurotransmitter release (Ghijsen and Leenders, 2005) . In the present work, we used this preparation to evaluate the VIP receptors and transduction pathways involved in the presynaptic enhancement of GABA release caused by VIP.
Methods

Animals
All animal care and experimental procedures were performed in accordance with the Portuguese law and the European Community (86/609/EEC) and ARRIVE guidelines. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Male outbred Wistar rats (5-6 weeks old) were purchased from Harlan Iberica (Barcelona, Spain) and housed in the local animal house until use. Animals were maintained under a 12:12 h light/dark cycle at a temperature of 22°C, with food and water ad libitum.
Preparation of isolated nerve terminals
[ 3 H]-GABA release experiments were carried out using hippocampal nerve terminals isolated from rats and the preparation of these nerve terminals is described below. Briefly, two hippocampi were homogenized in 4 mL ice-cold sucrose solution (sucrose 0.32 M, EDTA 1 mM, HEPES 10 mM and BSA 1 mg·mL À1 , pH 7.4) and centrifuged at 3000× g for 10 min at 4°C; the supernatant was then centrifuged at 14 000× g for 12 min at 4°C, and the pellet resuspended in 3 mL of a Percoll 45% (v·v À1 ) in modified artificial CSF solution (aCSF) without calcium (mM: NaCl 140, EDTA 1, HEPES 10 and KCl 5, glucose 5, pH 7.4). After centrifugation at 14 000× g for 2 min at 4°C, the top layer (which corresponds to the synaptosomal fraction) was washed twice with modified aCSF without Ca 2+ . The pellet (synaptosomal fraction) was resuspended in complete aCSF (mM: NaCl 125, KCl 3, glucose 10, MgSO 4 1.2, NaH 2 PO 4 1, CaCl 2 1.5 and HEPES 10, pH 7.4) containing 0.1 mM (aminooxy)acetic acid (AOAA) to avoid GABA catabolism by 4-aminobutyrate aminotransferase. The protein content of the hippocampal synaptosomal fraction was determined by the Lowry method modified according to Peterson (1977) using BSA as a standard. (Cunha et al., 1997) . In test conditions, VIP was present from the 16th (6 min before S 2 ) up to the 32nd minute after starting sample collection. When testing the action of VIP in the presence of other drugs, these were present from 15 min before starting sample collection until the end of the experiment. The radioactivity measurements were normalized to the total amount of tritium retained by the synaptosomes at the end of experiment that reflected the total radioactivity loaded. The amount of radioactivity released by stimulation was calculated by integration of the area under the evoked peak of tritium release after subtraction of basal tritium release. Effects (taken as % change) were evaluated by modification of the S 2 /S 1 ratios in test and control conditions. Synaptosomal disruption was evaluated by comparing LDH activity in the incubation bath with that found in the synaptosomal pellet upon its solubilization with 2% (v·v À1 )
Triton X-100 (Keiding et al., 1974) .
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2015/16 (Alexander et al., 2015a,b,c,d) .
Results
Under the conditions used in this study, the amount of tritium retained by the synaptosomes at the beginning of sample collection was 6.82 ± 0.46 × 10 10 Bq·mg protein
À1
(n = 160). In the absence of added drugs, the basal release of tritium was 4.08 ± 0.56 × 10 7 Bq·mg protein À1 (n = 72). Stimulation of synaptosomes with 25 mM K + for 2 min caused an approximate sixfold increase in the amount of tritium released to (2.36 ± 0.32) × 10 8 Bq·mg protein À1 (n = 72)
for S 1 and 1.98 ± 0.17 × 10 8 Bq·mg protein À1 (n = 72) for S 2 (S 2 /S 1 ratio -0.815 ± 0.007, n = 72). Addition of 0.5 mM EGTA and reduction of the extracellular calcium concentration to 200 nM during S 2 decreased the S 2 /S 1 ratio to 0.435 ± 0.012 (n = 6), inhibiting by 51.3 ± 5.0% (n = 6) evoked tritium release, compared with matched controls (S 2 /S 1 ratio: 0.848 ± 0.009, n = 6), in agreement to what was previously observed (Kirk and Richardson, 1994) . To investigate the relative contribution of voltage-gated calcium channels (VGCCs) and GABA transporter 1 (GAT-1) carrier reversal on [ 3 H]-GABA release, we used selective inhibitors.
In control conditions, the S 2 /S 1 ratio obtained was 0.818 ± 0.012 (n = 5). Addition of the VGCC inhibitor CdCl 2 (200 μM) (Nachshen, 1985) before S 2 decreased the S 2 /S 1 ratio to 0.393 ± 0.017 (n = 5), thus inhibiting by 50.9 ± 1.9% (n = 5) the evoked tritium release. When the selective GAT-1 inhibitor SKF89976A (20 μM) (Yunger et al., 1984; Borden et al., 1994) was present during S 2 , the S 2 /S 1 ratio decreased to 0.592 ± 0.046 (n = 5), inhibiting evoked tritium release by 27.2 ± 4.9% (n = 5). When applied simultaneously during S 2 , the VGCC inhibitor and of the GAT-1 inhibitor reduced by 73.2 ± 3.8% (n = 5) the evoked tritium release.
In these experiments, synaptosomal disruption was small since only 12.7 ± 0.6% (n = 4) of the total LDH activity (EC 1.1.1.27) was found at the end of an experiment upon superfusion of the synaptosomes in closed circuit.
in a biphasic manner (Cunha-Reis et al., 2004) . The maximum effect of VIP is obtained at 1 nM and is abolished in the presence of [Ac-Tyr 1 , D-Phe 2 ] GRF (1-29) (300 nM) (Cunha-Reis et al., 2004) , an antagonist of VIP receptors that does not discriminate between VIP receptor subtypes and in a concentration that can selectively block VIP receptors (Waelbroeck et al., 1985; Liu et al., 2000) , but no other receptors of the family present in the hippocampus. This biphasic nature of VIP action suggests that more than one mechanism mediates VIP action on GABA release. GABA release of 51.0 ± 3.2% (n = 12, Figure 1A ) in the absence of other drugs. In the presence of the VPAC 1 receptor antagonist, PG 97-269 (100 nM), the excitatory effect of VIP (1 nM) on K + -evoked [ 3 H]-GABA release was enhanced (F (3, 22) = 65.05; n = 5, Figure 1E ) . When the VPAC 2 receptor antagonist, PG 99-465 (100 nM), was present, the effect of 1 nM VIP was reversed (F (3, 22) = 65.05; n = 5,), now inhibiting K + -evoked [ 3 H]-GABA release ( Figure 1E ). When applied to the synaptosomes from the beginning of the experiment, PG 97-269 (100 nM, n = 5) and PG 99-465 (100 nM, n = 5) caused a significant decrease in the S 2 /S 1 ratios in control conditions ( Figure 1D , F (5, 30) = 45.57).
The results above described suggest that VPAC 1 and VPAC 2 receptors exert opposing effects on [
3 H]-GABA release.
To confirm this hypothesis, the action of the VPAC 1 selective agonist [K 15 , R 16 , L 27 ] VIP (1-7)/GRF (8-27) and of the VPAC 2 selective agonist RO 25-1553 (Gourlet et al., 1997c) . RO 25-1553 was used in a concentration (10 nM) that caused near maximal enhancement of [ 3 H]-GABA release without significant attenuation of the response. This concentration is also 10 times its IC 50 for VIP binding to rat VPAC 2 receptors expressed in CHO cells (Vertongen et al., 1997a) and binds negligibly to rat VPAC 1 or rat PAC 1 receptors (Gourlet et al., 1997c) .
To investigate the transmitter release mechanisms (exocytotic vs. carrier reversal) involved in VIP enhancement of [ 3 H]-GABA release, we investigated the role of VGCCs and the GAT-1 carrier-mediated processes in the effects of VIP and VIP receptor agonists. Upon blockade of VGCCs with CdCl 2 (200 μM) (Nachshen, 1985) , the effect of 1 nM VIP was strongly attenuated (F (2, 19) = 17.26, n = 5, Figure 3A ). Selective blockade of the GAT-1 carrier using SKF89976A (20 μM) (Yunger et al., 1984; Borden et al., 1994) caused a smaller reduction in the effect of 1 nM VIP (F (2, 19) = 17.26, n = 5, Figure 3A ). Upon blockade of VGCCs with CdCl 2 (200 μM), the inhibitory effect of the VPAC 1 agonist [K 15 , R 16 , L 27 ] VIP (1-7)/GRF (8-27) (10 nM) was reduced (F (2, 12) = 15.47, n = 4, Figure 3B ), and the enhancement of Figure 3C ). When applied to the synaptosomes from the beginning of the experiment, CdCl 2 (200 μM, n = 13) caused an enhancement in the basal release and decreased the release evoked by stimulation. CdCl 2 (200 μM, n = 13), but not SKF89976A (20 μM, n = 13), caused an increase in the S 2 /S 1 ratio in control conditions to 1.250 ± 0.008. Because VIP-mediated actions in the hippocampus have previously been associated with an increase of intracellular cAMP (Wright and Schoepp, 1996) , the involvement of the cAMP-mediated transducing system in VIP facilitation of [ 3 H]-GABA release was investigated using the PKA inhibitor, H-89 (Chijiwa et al., 1990 Figure 4A ). Some VIP-mediated actions in the nervous system have been associated with an increase in PKC activity (Gressens et al., 1998) and do not depend on the G s /adenylate cyclase/PKA transduction pathway, such as VPAC 1 -mediated actions on synaptic transmission in the hippocampus, which are dependent on PKC but not PKA activity (Cunha-Reis et al., 2005) . As PKC activation is also known to enhance GABA release (Capogna et al., 1995) , we investigated whether VIP facilitation of GABA release was dependent on PKC activity. By preventing PKC activation with 1 μM GF-109203X (Toullec et al., 1991) , the excitatory effect of 1 nM VIP on [
3 H]-GABA release was only slightly inhibited (F (10, 38) = 63.10, n = 5, Figure 4A ). However, as shown in Figure 4A , simultaneous PKA and PKC inhibition with H-89 (1 μM) together with GF-109203X (1 μM) abolished (F (10, 38) = 63.10) VIP facilitation of [ 3 H]-GABA release. Ca 2+ /calmodulin-dependent protein kinase II (CamKII) is known to modulate GABA release (Sitges et al., 1995) . To assess the contribution of CamKII to the effects of VIP on GABA release, we used a selective CamKII inhibitor, KN-62. In the presence of KN-62 (50 μM), the excitatory effect of 1 nM VIP was strongly inhibited (F (10, 38) = 63.10, n = 5, Figure 4A Figure 4B ), and the enhancement of [ 3 H]-GABA release caused by RO 25-1553 was abolished (F (7, 26) = 29.59, n = 4, Figure 4C ). Figure 4B ). The enhancement of [ 3 H]-GABA release caused by RO 25-1553 (10 nM) was also inhibited (F (7, 26) = 29.59, n = 4, Figure 4C ) in the presence of GF 109203X (1 μM). H-89 (1 μM) and GF proteins was tested using cholera toxin, which desensitizes G s -mediated responses by promoting ADP ribosylation of the G sα subunit of G s proteins, stabilizing the dissociation of α and βγ subunits and causing persistent activation of adenylate cyclase (Cassel and Pfeuffer, 1978) . In preparations treated with cholera toxin (100 ng·mL À1 ), the enhancement caused by 1 nM VIP on [ 3 H]-GABA release was turned into an inhibition (F (10, 38) = 63.10, n = 4, Figure 5A ). Figure 5D ). GABA release was enhanced (F (10, 38) = 63.10, n = 4, Figure 5B ). Pertussis toxin (100 ng·mL À1 ) abolished (F (6, 22) = 28.82, Figure 5C ) the inhibition of Figure 5D ) the enhancement of [ 3 H]-GABA release caused by the VPAC 2 agonist RO 25-1553 (10 nM). Aiming to elucidate the transduction pathways lying downstream of VPAC 2 -mediated activation of G s and VPAC 1 mediated activation G i , we tested the influence of PKA and PKC inhibitors on the effects of VPAC 1 and VPAC 2 receptor agonists observed upon treatment with either cholera toxin or Pertussis toxin. In the presence of cholera toxin (100 ng·mL À1 ), the inhibition caused by 1 nM VIP on [ 3 H]-GABA release (F (10, 38) = 63.10, n = 4, Figure 5A ) was not changed by the presence of H-89 (1 μM) but was mildly although not significantly attenuated (F (10, 38) = 63.10, n = 4, Figure 5A ) in the presence of the PKC inhibitor GF109203X (1 μM). Figure 5C ) was similarly not changed (F (6, 22) = 28.82, Figure 5C ) by the presence of H-89 (1 μM) but was again only mildly but not significantly attenuated (F (6, 22) = 28.82, n = 4, Figure 5C ) in the presence of the PKC inhibitor GF109203X (1 μM). Upon blockade of G i/o proteins using Pertussis toxin (100 ng·mL À1 ), the enhancement caused by 1 nM VIP of [ 3 H]-GABA release (n = 4, Figure 5B ) was abolished (F (10, 38) = 63.10, n = 3) by the presence of H-89 (1 μM) and was markedly attenuated (F (10, 38) = 63.10, n = 3, Figure 5B ) in the presence of the PKC inhibitor GF109203X (1 μM). The facilitation caused by RO 25-1553 (10 nM) in the presence of Pertussis toxin (100 ng·mL À1 ) on [ 3 H]-GABA release (n = 4, Figure 5D) was blocked (F (7, 26) = 29.59, n = 3, Figure 5D ) by H-89 (1 μM) and was markedly attenuated (F (7, 26) = 29.59, n = 3, F (7, 26) = 29.59, Figure 5D ) by the PKC inhibitor GF109203X (1 μM). The presence of cholera toxin (100 ng·mL À1 ) or
Pertussis toxin (100 ng·mL À1 ) throughout the experiment increased the basal release and the release evoked by stimulation (S 1 and S 2 ). The S 2 /S 1 ratio in control conditions in the presence of cholera toxin (100 ng·mL À1 ) was reduced to 0.698 ± 0.037 (n = 6) and in the presence of Pertussis toxin (100 ng·mL À1 ) was reduced to 0.669 ± 0.012 (n = 6). When the toxins were applied together with either H-89 (1 μM) or GF 109203X (1 μM) throughout the experiment, the differences in basal and evoked release were not significant except when Pertussis toxin (100 ng·mL À1 ) was co-applied with GF 109203X (1 μM) for which the S 2 /S 1 ratio in control conditions was 0.683 ± 0.016 (n = 3).
Trying to elucidate which transduction pathways were involved in either VGCC-dependent or GAT-1-dependent components of VPAC 2 -mediated enhancement of [ 3 H]-GABA release, we tested the influence of PKA and PKC inhibitors on VPAC 2 -mediated effects remaining after GAT-1 blockade or VGCC blockade. When VGCCs were blocked with CdCl 2 (200 μM), the remaining effect of RO 25-1553 (11.0 ± 1.6%, n = 4) was not changed (n = 3, Figure 6A ) by the PKA inhibitor H-89 (1 μM) but was abolished (F (6, 22) = 30.95, n = 3, Figure 6A ) by the PKC inhibitor GF 109203X (1 μM). When the GAT-1 uptake carrier was blocked using SKF89976A (20 μM), the effect of RO 25-1553 (n = 4) was abolished (F (6, 22) = 30.95, n = 3, Figure 6B ) in the presence of the PKA inhibitor H-89 (1 μM) but was attenuated (n = 3, F (6, 22) = 30.95, Figure 6B ) by the PKC inhibitor GF 109203X (1 μM). GRF (8-27) (10 nM, C) and the VPAC 2 receptor antagonist RO 25-1553 (10 nM, D) tested alone, in the presence of cholera toxin (ChTx) or Pertussis toxin (PTx) together with either the PKA inhibitor (H-89) or the PKC inhibitor (GF109203X) in hippocampal nerve terminals. The effect of VIP or selective agonists was calculated by comparing the S 2 /S 1 ratio obtained in test (presence of VIP or VIP receptor agonists during S 2 ) and in control conditions. Each bar represents the mean ± SEM of results obtained in 3-12 experiments. ★ P < 0.05, significantly different from VIP or selective agonists alone or, VIP or agonists in the presence of either ChTx or PTx; ANOVA, followed by Sidak's multiple-comparison test.
Discussion
The main findings of the work here described are that (i) VIP, through activation of both VPAC 1 and VPAC 2 receptors, exerts opposing actions on GABA release from hippocampal nerve terminals, VPAC 1 receptor inhibiting and VPAC 2 receptor enhancing GABA release; (ii) VPAC 2 receptor activation not only enhances VGCC-dependent GABA exocytosis through a G s -dependent, PKA-dependent and PKC-dependent mechanism but also enhances GAT-1 carrier-mediated GABA outflow through a G s -dependent and PKC-dependent (but not PKA-dependent) mechanism; (iii) VPAC 1 receptor activation inhibits VGCC-dependent GABA exocytosis through a G i/o , PKA-independent and partly PKC-dependent mechanism; and (iv) both VPAC 1 and VPAC 2 receptors are present in GABAergic hippocampal nerve terminals. The work described in this paper suggests that VPAC 2 receptor activation is the trigger for the prevailing VIP enhancement of GABA release, because VIP was not able to enhance GABA release in the presence of the VPAC 2 selective antagonist PG 97-269, and the selective VPAC 2 receptor agonist RO 25-1553 enhanced GABA release. This VPAC 2 -mediated action appears to be mediated by sequential activation of G s proteins, adenylate cyclase and PKA (see Figure 7 ) as the enhancement of GABA release caused by the VPAC 2 receptor activation was abolished by desensitizing G s -mediated responses with cholera toxin or by inhibiting PKA activity ( Figures 4C and 5D ). PKA is a known modulator of the exocytotic pathway in several types of secretory cells (Evans and Morgan, 2003) , where it is involved in enhancement of both the priming and fusion steps of vesicle exocytosis through phosphorylation of several proteins of the exocytotic machinery. As VIP and the selective VPAC 2 receptor agonist enhance GABA release through a G s -dependent and PKA-dependent mechanism that also depends largely on VGCC activity ( Figure 3A) , regulation of PKA activity and its actions on the exocytotic machinery is likely to be the main mechanism involved in VPAC 2 receptor-mediated enhancement of GABA release. VPAC 2 -mediated actions on GABA release through exocytosis were also partly dependent on PKC activity. This serine/threonine kinase is another key modulator of the exocytotic machinery (Morgan et al., 2005) , having multiple exocytotic protein targets. The fact that PKA inhibition alone, independently of PKC activation levels, could block the enhancement of GABA release caused by VIP or the VPAC 2 receptor agonist in the presence of CdCl 2 
Figure 7
Schematic representation of the main mechanisms involved in VPAC 2 -mediated VIP enhancement of GABA release from hippocampal nerve terminals. AC, adenylate cyclase; G sα , G s protein α subunit; VPAC 2 R, VPAC 2 receptor.
suggests that the PKC-dependent step in VPAC 2 -mediated enhancement of exocytotic GABA release lies downstream of PKA regulation. VPAC 2 receptor activation also enhances GABA outflow through the GAT-1 nerve terminal carrier as shown by the attenuation of VIP-mediated and VPAC 2 agonist-mediated enhancement of GABA release in the presence of the selective inhibitor of the GAT-1 carrier, SKF89976A. This GABA release mechanism is thought to be more important in pathological conditions that induce elevation of extracellular K + such as hypoxia/ischaemia, trauma or epileptic seizures (Raiteri et al., 2002; Allen et al., 2004) . Although a minor component of VIP enhancement of GABA release under the stimulation conditions that were used in this work, the ability of VIP to enhance GAT-1-mediated GABA release might constitute an important regulatory mechanism in the control of GABA outflow under such stressful or pathological conditions. VPAC 2 receptor mediated enhancement of GABA release through the GAT-1 carrier was dependent on protein G s and PKC activity, but not on PKA activity, suggesting a regulation mechanism independent of adenylate cyclase. VPAC 2 -mediated enhancement of GABA outflow through a PKC-dependent mechanism might involve a PKC-mediated recruitment of GAT-1 to the membrane (Quick et al., 1997 (Quick et al., , 2004 , allowing an enhancement of GABA outflow upon depolarization-induced reversal of the carrier. It is possible that different PKC subtypes are involved in VPAC 2 -mediated regulation of exocytotic and GAT-1-mediated GABA release. The finding that both PKA and PKC contribute synergistically to the enhancement of GABA release by VIP and the VPAC 2 receptor agonist is in agreement with previous observations that stimulation of either PKA or PKC enhances inhibitory synaptic transmission through independent presynaptic mechanisms of action (Capogna et al., 1995) . VPAC 1 receptor activation inhibited GABA release, as shown by the facilitation of VIP enhancement of GABA release in the presence of the selective VPAC 1 receptor antagonist PG 97-269 and by the inhibition of GABA release caused by the VPAC 1 agonist [K 15 , R 16 , L 27 ] VIP (1-7)/GRF (8-27).
This VPAC 1 receptor-mediated inhibition of GABA release is dependent on activation of G i proteins and VGCCs and partly dependent on PKC activity (see Figure 8 ). This implies that VPAC 1 -mediated inhibition of GABA release involved two different mechanisms, one involving VGCCs and PKC and other dependent on VGCCs but not on PKC. The first mechanism may involve activation of PLC β by the release of G βγ subunits from G i proteins (Clapham and Neer, 1997) and subsequent activation of PKC. Although it is currently established that PKC is a key modulator of the exocytotic machinery, the role of different PKC isoforms in this regulation is not known (Parker and Murray-Rust, 2004) . Furthermore, the consequences for neurotransmitter release of PKC-mediated phosphorylation of proteins of the exocytotic machinery remain controversial (Morgan et al., 2005) as PKC mediates both enhancement and inhibition of exocytotic GABA release. The second mechanism for G i -dependent VPAC 1 receptor-mediated inhibition of GABA release may involve a direct inhibition of VGCCs by G βγ subunits (Jarvis and Zamponi, 2001b) or an interaction of the G βγ subunits with proteins of the exocytotic machinery, as has been described with SNAP-25 and synapsin-1 (Jarvis and Zamponi, 2001a; Gerachshenko et al., 2005) . Any of these actions would cause a VGCC-dependent inhibition of GABA release. The fact that the VPAC 1 receptor is operating in a G i -dependent (instead of a G s -dependent) manner is not surprising as the ability of the VPAC 1 receptor to couple to G i proteins has previously been observed in CHO cells and hippocampal membranes (van Rampelbergh et al., 1997; Shreeve, 2002) . The present study provides functional evidence for the presence of VPAC 1 and VPAC 2 receptors in hippocampal GABAergic nerve terminals. The opposing actions of VPAC 1 or VPAC 2 receptor activation on hippocampal GABA release may be related to the different hippocampal distribution of VPAC 1 and VPAC 2 receptors and to a differential target selectivity of terminals containing each of the receptors. VPAC 1 and VPAC 2 receptor mapping in the hippocampus by in situ hybridization, autoradiography or immunohistochemistry Joo et al., 2004; White et al., 2010) demonstrates a preferential location of VPAC 1 receptors in the stratum oriens and radiatum and VPAC 2 receptors in the stratum piramidale of the Ammon's horn. This distribution overlaps with the differential location of synapses of VIPcontaining interneurones targeting other interneurones (stratum oriens and radiatum) and VIP-containing basket cells targeting pyramidal cell bodies (Acsády et al., 1996b) respectively. Thus, it is possible that VPAC 1 and VPAC 2 receptors are differently involved in the modulation of GABA release to interneurones and pyramidal cells. An unequivocal demonstration of this hypothesis would require a finer localization the immunocytochemical signal at nerve terminals from the different interneurone populations. This, together with either paired recordings or channel rhodopsin-assisted circuit mapping would be required to elucidate the dual effect of VIP on GABA release. This approach has been used recently to discriminate the role of different VIP-expressing cortical interneurones in a push-pull inhibitory circuit (GarciaJunco-Clemente et al., 2017) . A differential modulation of GABA release to interneurones and pyramidal cells by VIP is consistent with the current knowledge that GABAergic transmission to interneurones and to pyramidal cells is differently regulated (Jonas et al., 2004) and with previous evidence (Cunha-Reis et al., 2005 , 2006 ) that VPAC 1 receptor Figure 8 Schematic representation of the main mechanisms involved in VPAC 1 -mediated inhibition of GABA release from hippocampal nerve terminals. G iα ,G i protein α subunit; G iβγ ,G i protein β-γ dimer; VPAC 1 R, VPAC 1 receptor 1.
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activation is mainly associated with VIP modulation of synaptic transmission to pyramidal cell dendrites, whereas VPAC 2 receptor activation is preferentially associated with modulation of transmission to pyramidal cell bodies. The present observation that upon VPAC 1 receptor blockade with PG 97-269 there is an enhancement of the facilitation caused by VIP on GABA release (mediated by VPAC 2 receptor activation) suggests that a concomitant regulation of GABA release by VPAC 1 and VPAC 2 receptors, which might be present at the same nerve terminal, could occur, provided that the superfusion rates used in this study were sufficient to eliminate interactions between different terminals (Collard, 1996) .
Neuropeptides, such as VIP, are stored in 'special' vesicles known as large dense-core vesicles that are released from synaptic sites different from the active zone, where the release of classic transmitters like GABA or glutamate occurs. Neuropeptide release is also coupled to different VGCCs, and it requires strong and repetitive electrical activity patterns (see Ghijsen and Leenders, 2005) , like tetanic stimulation. As such, the physiologically relevant actions of VIP in the control GABA release are likely in situations eliciting synaptic plasticity phenomena or in pathological conditions like epilepsy. VIP was shown to modulate long-term depression and de-potentiation induced by low-frequency stimulation (Cunha-Reis et al., 2014) . In fact, a marked increase in VIP receptor binding sites was reported in the hippocampus of humans with temporal lobe epilepsy with multiple sclerosis (de Lanerolle et al., 1995) , a disease that is also associated with marked changes in the nature and distribution of inhibitory circuits (Cossart et al., 2001; Sloviter, 2005) .
In summary, this study clearly demonstrates that VIP modulates GABA release from hippocampal nerve terminals through the activation of both VPAC 1 and VPAC 2 receptors, which recruit and interact with multiple intracellular pathways. VPAC 1 receptors inhibit GABA release through G i/o coupling. Conversely, VPAC 2 receptors enhance GABA release by coupling to G s proteins. Differences in VIP modulation of distinct populations of nerve terminals may occur and may play an important role in the differential modulation by VIP of GABA release to interneurones, pyramidal cell dendrites or pyramidal cell bodies. This suggests that further studies in hippocampal slices could provide important insights into the effects of presynaptic activation of VIP VPAC 1 and VPAC 2 receptors on hippocampal microcircuits.
